Barclays analyst Steve Valiquette lowered the firm’s price target on Humana (HUM) to $585 from $620 and keeps an Overweight rating on the shares. Following UnitedHealth’s (UNH) MLR comments, Humana also confirmed Medicare outpatient volume is running higher, which will drive Q2 and full-year MLR to the high end of the 86.3%-87.3% MLR guide range, the firm said in a research note on Friday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HUM:
- Wells Fargo Sees Potential Purchase Window in Managed Care Stocks
- Evolent selloff on MCOs’ utilization comments ‘way overdone,’ says RBC Capital
- Humana management to meet with Truist
- Humana backs FY23 adjusted EPS view of ‘at least’ $28.25, consensus $28.34
- UNH Slide Prompts a Catastrophe for Health Insurer Stocks